Latest Headlines

Latest Headlines

Widespread, early flu season grips United States

A fast, early and widespread flu season has gripped the United States, though deaths and hospitalizations are still below pandemic thresholds.

Emergent, VaxInnate sign pandemic flu vaccine deal

Emergent BioSolutions snagged the exclusive right to manufacture and sell VaxInnate's flu vaccine, a product Emergent can produce quickly at high yields and low cost.

FDA extends approval of Roche's Tamiflu

Roche has spent the past few months getting raked over the coals by critics who say the company has not offered full and complete access to Tamiflu data. So when the FDA extended the approval of the flu drug, the news came as a much-needed boost.

Georgia State scientists investigate universal flu vaccine

A universal influenza vaccine is the virtual Holy Grail for flu scientists, and a researcher and his collaborators at Georgia State University's Center for Inflammation, Immunity and Infection moved a step closer to developing the elusive shot.

FDA approves GSK's quadrivalent flu vaccine

The FDA gave the OK to GlaxoSmithKline's new four-strain seasonal flu vaccine, which the company said will become available for the 2013-2014 flu season.

Flu season arrives a month early

An early flu season is under way, the national Centers for Disease Control and Prevention reports, and will likely prove formidable.

CureVac, German scientists take aim at faster flu vaccine

When it comes to flu pandemics, making and distributing vaccines quickly is of utmost importance. And now German scientists have developed an RNA vaccine that could cut flu vaccine production time from months to weeks.

Top 10 selling flu vaccines of 2012

What do less-than-stellar vaccination rates mean for sales? Looking at actual worldwide 2011 sales numbers and estimated worldwide 2012 sales numbers provided by EvaluatePharma, it seems sales as a whole are only slightly up for the top 10 best-selling flu vaccines. Read more >>

Italy ends ban on Novartis flu vaccine

Italy lifted a ban on Novartis' flu vaccine several weeks after halting distribution due to small virus particles found in some injections.

Gates Foundation backs $13M venture add for flu drug developer

The Bill & Melinda Gates Foundation has stepped up with another equity investment in a biotech company, this time making a major contribution to a $13 million Series A add for a startup aiming at a universal preventive as well as therapeutic approach to influenza. Omega Funds also joined the venture top-up, bringing the first venture round for Cambridge, MA-based Visterra to $26 million.